{
    "Trade/Device Name(s)": [
        "RAMP\u00ae NT-proBNP Assay",
        "NT-proBNP immunological test system"
    ],
    "Submitter Information": "Response Biomedical Corporation",
    "510(k) Number": "K063662",
    "Predicate Device Reference 510(k) Number(s)": [
        "K022516",
        "K032646",
        "K051382",
        "K051596"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "April 22, 2008",
    "Summary Letter Received Date": "April 23, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine",
        "POCT"
    ],
    "Analyte(s)": [
        "N-terminal pro-brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Whole Blood (EDTA)"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RAMP reader"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic fluorescence immunoassay"
    ],
    "Methodologies": [
        "Immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test Cartridge",
        "Reagent",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for RAMP NT-proBNP quantitative immunochromatographic assay measuring NT-proBNP in EDTA whole blood using RAMP reader",
    "Indications for Use Summary": "Quantitative in vitro diagnostic measurement of NT-proBNP in EDTA whole blood to aid diagnosis and assessment of severity in suspected heart failure and risk stratification in heart failure patients",
    "fda_folder": "Clinical Chemistry"
}